ResearchMoz

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

GBI Research
Published Date » 2013-04-15
No. Of Pages » N/A

ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment

GBI Research, the leading business intelligence provider, has released its latest research: “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. 

The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. 

The ADHD therapeutics market is expected to show strong growth in Spain and Japan, with Compound Annual Growth Rates (CAGRs) of 8% and 15% respectively. However, the total revenues of these markets are still expected to be much lower than the largest market, the US, which is expected to reach $6,260m by 2018. This is due to the much higher diagnosis rates for both adults and children with ADHD in the US.

Scope

  • Current and future treatment and diagnosis trends for ADHAD
  • Market forecasts for ADHD across seven major markets
  • Analysis of the developmental pipelines for ADHD
  • Information on recent industry deals
Reasons to Buy

  • Understand how the ADHD market has developed and is continuing to develop within the featured markets
  • Predict which products are likely to be most successful in the future
  • Gain an understanding of the possible market available for specific products
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to 2018 – Executive Summary

3 ADHD Therapeutics Market to 2018 – Introduction
3.1 Etiology and Pathophysiology
3.1.1 Genetic Influences
3.1.2 Environmental Influences
3.1.3 Pathophysiology
3.2 Epidemiology
3.2.1 Child/Adult Subpopulations
3.2.2 Male/Female
3.3 Diagnosis
3.3.1 DSM-IV Criteria for ADHD
3.3.1.1 DSM-V Revision
3.3.2 ICD-10 Criteria for Hyperkinetic Disorder
3.3.3 Diagnostic Rating Scales
3.3.4 Issues with Diagnosis
3.3.5 Co-Morbid Disorders
3.4 Treatment and Management Options
3.4.1 Pharmacologic Treatment
3.5 Drivers and Barriers for ADHD Therapeutics Market
3.5.1 Drivers
3.5.1.1 High Prevalence of ADHD
3.5.1.2 Need for Effective Non-Stimulant Therapies
3.5.2 Barriers
3.5.2.1 Increasingly Competitive Market
3.5.2.2 Social Factors
3.5.2.3 High Level of Co-Morbidity
3.6 Report Guidance

4 ADHD Therapeutics: Market Characterization by Geography
4.1 All Major Markets
4.1.1 Market Size – All Major Markets
4.1.2 Market Forecast – All Major Markets
4.1.3 Annual Cost of Therapy – Average of All Major Markets
4.2 The US
4.2.1 Market Size – The US
4.2.2 Market Forecast - The US
4.2.3 Annual Cost of Therapy – The US
4.3 Top 5 Countries of Europe
4.3.1 Market Size – France
4.3.2 Market Forecast – France
4.3.3 Annual Cost of Therapy – France
4.3.4 Market Size – Germany
4.3.5 Market Forecast – Germany
4.3.6 Annual Cost of Therapy – Germany
4.3.7 Market Size – Italy
4.3.8 Market Forecast – Italy
4.3.9 Annual Cost of Therapy – Italy
4.3.10 Market Size – Spain
4.3.11 Market Forecast – Spain
4.3.12 Annual Cost of Therapy – Spain
4.3.13 Market Size – The UK
4.3.14 Market Forecast – The UK
4.3.15 Average Annual Cost of Therapy – The UK
4.4 Japan
4.4.1 Market Size – Japan
4.4.2 Market Forecast – Japan
4.4.3 Annual Cost of Therapy – Japan

5 ADHD Therapeutics Market to 2018 – Competitive Landscape
5.1 Overview of Major Marketed Products in the ADHD market
5.1.1 Adderall XR (mixed amphetamine salt)
5.1.1.1 Overview
5.1.1.2 Efficacy
5.1.1.3 Safety
5.1.2 Daytrana (methylphenidate transdermal patch)
5.1.2.1 Overview
5.1.2.2 Efficacy
5.1.2.3 Safety
5.1.3 Concerta (methylphenidate hydrochloride)
5.1.3.1 Overview
5.1.3.2 Efficacy
5.1.3.3 Safety
5.1.4 Intuniv (guanfacine)
5.1.4.1 Overview
5.1.4.2 Efficacy
5.1.4.3 Safety
5.1.5 Strattera (atomoxetine hydrochloride)
5.1.5.1 Overview
5.1.5.2 Efficacy
5.1.5.3 Safety
5.1.6 Vyvanse (lisdexamfetamine dimesylate)
5.1.6.1 Overview
5.1.6.2 Efficacy
5.1.6.3 Safety
5.1.7 Kapvay (clonidine hydrochloride)
5.1.7.1 Overview
5.1.7.2 Efficacy
5.1.7.3 Safety
5.1.8 Focalin XR (dexmethylphenidate hydrochloride)
5.1.8.1 Overview
5.1.8.2 Efficacy
5.1.8.3 Safety
5.1.9 Generic products

6 ADHDTherapeutics Market to 2018 – Product Pipeline Analysis
6.1 Introduction
6.2 ADHD Therapeutics Pipeline – Pipeline by Phases of Development
6.3 Trends in the ADHD Therapeutic Pipeline

7 ADHD Therapeutics Market to 2018 – Strategic Consolidations
7.1 Overview
7.1.1 Deals by Deal Type
7.1.2 Deals by Year
7.1.3 Deals by Geography
7.1.4 Deals by Value
7.2 M&A Landscape
7.2.1 M&A Deals by Deal Type
7.2.2 M&A Deals by Year
7.2.3 M&A Deals by Geography
7.2.4 M&A Deals by Deal Value
7.2.5 Sanofi-Aventis Merger, 2004
7.3 R&D Licensing Agreements
7.3.1 Deals by Year
7.3.2 Deals by Geography
7.3.3 Deals by Deals Value
7.3.4 Targacept and AstraZeneca Agreement, 2009
7.4 Co-Development Agreements
7.4.1 Deals by Year
7.4.2 Deals by Geography
7.4.3 Deals by Deal Value
7.4.4 Shire and New River Co-Development Deal, 2005

8 Appendix
8.1 Abbreviations
8.2 Research Methodology
8.2.1 Coverage
8.2.2 Secondary Research
8.2.3 Primary Research
8.2.4 Market Size by Geography
8.3 Geographical Landscape
8.4 Pipeline Analysis
8.5 Competitive Landscape
8.5.1 Expert Panel Validation
8.6 Contact Us
8.7 Disclaimer
8.8 Sources
8.9 Disclaimer

List of Tables

Table 1: DSM-IV criteria for attention deficit hyperactivity disorder
Table 2: CD-10 criteria for hyperkinetic disorders
Table 3: ADHD Therapeutics, Marketed Products Overview, 2012
Table 4: ADHD Therapeutics, Pre-Clinical Pipeline, 2012
Table 5: ADHD Therapeutics, Phase I Pipeline, 2012
Table 6: ADHD Therapeutics, Phase II Pipeline, 2012
Table 7: ADHD Therapeutics, Phase III 2012
Table 8: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Table 9: M&A Deals by Deal Value

List of Figures

Figure 1: ADHD All Major Markets Market Size ($m) 2006-2011
Figure 2: ADHD All Major Markets Market Forecast ($m) 2012-2018
Figure 3: ADHD Annual Cost of Therapy All Markets ($) 2006-2018
Figure 4: ADHD Market Size US ($m) 2006-2011
Figure 5: ADHD Market Forecast US ($m) 2012-2018
Figure 6: ADHD Annual Cost of Therapy The US ($) 2006-2018
Figure 7: ADHD Market Size France ($m) 2006-2011
Figure 8: ADHD Market Forecast France ($m) 2012-2018
Figure 9: ADHD Annual Cost of Therapy France ($) 2006-2018
Figure 10: ADHD Market Size Germany ($m) 2006-2011
Figure 11: ADHD Market Forecast Germany ($m) 2012-2018
Figure 12: ADHD Annual Cost of Therapy Germany ($) 2006-2018
Figure 13: ADHD Market Size Italy ($m) 2006-2011
Figure 14: ADHD Market Forecast Italy ($m) 2012-2018
Figure 15: ADHD Annual Cost of Therapy Italy ($) 2006-2018
Figure 16: ADHD Market Size Spain ($m) 2006-2011
Figure 17: ADHD Market Forecast Spain ($m) 2012-2018
Figure 18: ADHD Annual Cost of Therapy Spain ($) 2006-2018
Figure 19: ADHD Market Size UK ($m) 2006-2011
Figure 20: ADHD Market Forecast UK ($m) 2012-2018
Figure 21: ADHD Annual Cost of Therapy The UK ($) 2006-2018
Figure 22: ADHD Market Size Japan ($m) 2006-2011
Figure 23: ADHD Market Forecast Japan ($m) 2012-2018
Figure 24: ADHD Therapeutics – Pipeline by Phase of Development, 2012
Figure 25: ADHD Therapeutics – Pipeline Molecules by Mechanism of Action, 2012
Figure 26: ADHD Therapeutics – Pipeline by Program Type, 2012
Figure 27: ADHD Therapeutics – Inactive/Discontinued Pipeline Molecules by Target, 2012
Figure 28: Total Deals by Deal Type
Figure 29: Total Deals by Year
Figure 30: Total Deals by Geography
Figure 31: Total Deals by Deal Value
Figure 32: M&A Deals by Deal Type
Figure 33: M&A Deals by Year
Figure 34: M&A Deals by Geography
Figure 35: R&D Licensing Agreements Deals by Year
Figure 36: R&D Licensing Agreements Deals by Geography
Figure 37: R&D Licensing Agreements Deals by DealsValue
Figure 38: Co-Development Agreements Deals by Year
Figure 39: Co-Development Agreements Deals by Geography
Figure 40: Co-Development Agreements Deals by Deal Value
Figure 41: GBI Research Market Forecasting Model

Upcoming Reports:

Active, Smart And Intelligent Packaging Market - Global Industry Analysis, Market Size, Market Share, Growth And Forecast, 2012 - 2018
By - Transparency Market Research
The active, smart and intelligent packaging (advanced packaging) refers to the packaging system used in pharmaceuticals, food and other products. Advanced packaging is rapidly replacing the traditional packaging system as it improves the visual appearance of the products by interacting internally and externally with the environment.  The global food packaging industry has witnessed significant growth in the last five years due to rising urban lifestyles and rising global population. North America is the largest regional market in the global advanced packaging market...
Food Traceability Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Traceability, a concept which has been in existence for a long time, which was limited to secret services of areas involving high risks or net worth, has seen a rise in application in the food safety and quality industry. Every step of logistics, right from packaging to the end consumer, now uses different techniques of food traceability for varied reasons. However, the core driver of the market has been the growing importance of the ability to track any food item to its origin. This is due to the rise in incidences of food borne diseases and outbreaks and due to complex...
Digital Cameras Market - Global Industry Analysis, Market Size, Market Share And Forecasts, 2012 - 2018
By - Transparency Market Research
The worldwide digital camera market is projected to grow to 138 million units by the year 2015 attributed by increasing demand for digital single lens reflex (SLR) cameras. Demand for digital SLR cameras is expected to witness significant growth in Asia Pacific due to the increasing income levels and growing prosperity of consumers.  Digital cameras represent one of the most popular segments of consumer electronics products market and it has benefited immensely from digitization of consumer electronics products. The global economic downturn hampered the growth of this...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...